SEC Filings

SEC Filings
Filing Date	Form	Description
January 19, 2023	6-K	On January 19, 2023, Biophytis S.A. issued a press release announcing that the Paris Court of appeal confirms the judgement of the Paris Commercial Court of 16th March 2021.
January 06, 2023	6-K	On January 5, 2023, Biophytis S.A. issued a press release announcing its participation in two major investor conferences in January, in the United States and in France : the JP Morgan Healthcare Conference and the Invest Securities Biomed Event.
November 30, 2022	6-K	On November 30, 2022, Biophytis S.A. issued a press release announcing the organization of a webcast with key opinion leaders (KOL) on the phase 2-3 COVA study results of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure.
October 31, 2022	6-K	On October 31, 2022, Biophytis S.A. issued a press release announcing the publication of its key financial figures as at 30 June 2022 and a restatement of the financial statements published as of December 31st, 2021 and providing and update on the operational milestones.
October 26, 2022	6-K	On October 26, 2022, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice.
September 15, 2022	6-K	On September 15, 2022, Biophytis S.A. issued a press release announcing that the company will participate in HCW 24th Annual Global Investment conference.
September 13, 2022	6-K	On September 13, 2022, Biophytis S.A. issued a press release announcing that the Paris Court of appeal rules in favour of Biophytis in the case against Negma Group Ltd.
September 07, 2022	6-K	On September 7, 2022, Biophytis S.A. issued a press release announcing very promising top line results of its phase 2-3 COVA clinical study in COVID-19 related to respiratory failure.
July 04, 2022	6-K	On July 4, 2022, Biophytis S.A. issued a press release providing an update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit.
June 30, 2022	6-K	On June 30, 2022, Biophytis S.A. issued a press release announcing the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million.
June 27, 2022	6-K	On June 27, 2022, Biophytis S.A. issued a press release presenting the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress.
June 22, 2022	6-K	On June 22, 2022, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting held on June 21, 2022.
June 16, 2022	6-K	On June 16, 2022, Biophytis S.A. issued a press release presenting preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease.
June 3, 2022	6-K	On June 3, 2022, Biophytis S.A. issued a press release announcing the Convening of Another Combined General Meeting at a Later Date.
May 12, 2022	6-K	On May 12, 2022, Biophytis S.A. issued a press release announcing its participation at the Bio International Convention in San Diego from the 13th to the 16th of June
April 21, 2022	20-F	Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For The Fiscal Year Ended December 31, 2021
April 19, 2022	6-K	On April 19, 2022, Biophytis S.A. issued a press release announcing that the company will present Sarconeos (Bio101) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston, April 20-22, 2022
April 7, 2022	6-K	On April 7, 2022, Biophytis S.A. issued a press release announcing 2021 Operational and Financial Results and Gives Updates on 2022 Perspectives
April 5, 2022	6-K	On April 5, 2022, Biophytis S.A. issued a press release announcing the appointment of Philippe Rousseau as Chief Financial Officer
March 16, 2022	6-K	On March 16, 2022, Biophytis S.A. issued a press release announcing that the company will participate in a key conference on mobility for the elderly
February 4, 2022	6-K	On February 3, 2022, Biophytis S.A. issued a press release announcing that the company received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program
December 23, 2021	6-K	On December 22, 2021, Biophytis S.A. issued a press release announcing the drawing of the last tranche of ORNANE under the 2020 Atlas contract for 3 million.
December 17, 2021	6-K	On December 16, 2021, Biophytis S.A. issued a press release announcing that the company is to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3
November 23, 2021	6-K	On November 22, 2021, Biophytis S.A. issued a press release announcing the obtaining of a new 10M€ loan structure with Kreos Capital
November 15, 2021	6-K	On November 15, 2021, Biophytis S.A. issued a press release announcing US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID 19
October 29, 2021	6-K	On October 29, 2021, Biophytis S.A. issued a press release reporting Restated Financial Statements for Previous Periods and as of June 30, 2021.
October 29, 2021	20-F	Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934 For The Fiscal Year Ended December 31, 2020
October 29, 2021	6-K	On October 28, 2021, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2021.
October 06, 2021	6-K	Biophytis S.A. issued a press release announcing it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia
October 05, 2021	6-K	On October 4, 2021, Biophytis S.A. issued a press release announcing the drawing of 2 new tranches of ORNANE under the 2020 Atlas contract for € 6 million
October 04, 2021	6-K	Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
September 30, 2021	6-K	Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29–October 2, 2021
September 17, 2021	6-K	Biophytis reports H1 2021 financial results and provides business update
September 15, 2021	6-K	Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19
June 30, 2021	6-K	Biophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be released by August 2021
June 30, 2021	6-K	Biophytis announces that it will secure the manufacturing of Sarconeos (BIO101) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 study
June 18, 2021	6-K	Biophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
May 12, 2021	6-K	Biophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
May 11, 2021	6-K	Results of the Combined General Meeting on May 10, 2021
April 30, 2021	6-K	Biophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholers
April 29, 2021	6-K	Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
April 27, 2021	6-K	Convening of another Combined General Meeting at a later date
April 26, 2021	6-K	Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
March 22, 2021	6-K	Biophytis gives update on its Phase 2-3 COVA study on COVID-19
March 19, 2021	6-K	Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
March 12, 2021	6-K	Annual General Meeting will take place on April 26, 2021
March 11, 2021	20-F	Annual Report for the Fiscal Year Ended Dec 31, 2020
Feb 26, 2021	6-K	Biophytis Reports 2020 Full Year Results
Feb 17, 2021	6-K	Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial
Feb 16, 2021	6-K	Report of Foreign Private Issuer
Feb 9, 2021		Final Prospectus
Feb 9, 2021	F-1	Amendment No 3
Feb 8, 2021	FWP	Free Writing Prospectus
Feb 4, 2021	F-8A	For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g)
Feb 4, 2021	F-1	Amendment No 2
Feb 2, 2021	FWP	Free Writing Prospectus
Feb 2, 2021	F-1	Amendment No 1
Jan 19, 2021	F-1	Form F-1
Dec 23, 2020	F-1	Draft Registration Statement
Nov 20, 2020	F-1	Draft Registration Statement